There is clinical evidence that inhibition of TNF-alpha is an effective therapy for treating both systemic and cutaneous sarcoidosis which is consistent the view that TNF-alpha plays a prominent role in the inflammatory process seen in these conditions [49–53]. This evidence concerns the gene TNF and skin sarcoidosis.